18th Oct 2007 16:39
Consort Medical PLC18 October 2007 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO ORFROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULDCONSTITUTE A VIOLATION OF THE LAWS OF SUCH JURISDICTION PRESS ANNOUNCEMENT FOR IMMEDIATE RELEASE 18 October 2007 CONSORT MEDICAL PLC ("CONSORT MEDICAL" OR THE "COMPANY"), FORMERLY BESPAK PLC The Board of Consort Medical plc has noted that Pfizer has decided to exitExubera(R) inhaled insulin. This decision follows the reduction in productionlevels previously disclosed by the Company in its announcement dated 27 June2007. It is expected that the closure of the Exubera(R) production line will notimpact the Company's current year adjusted* profit before tax. Furthermore, theBoard estimates that the net impact of the withdrawal from Exubera andassociated restructuring of the business will impact the adjusted* profit beforetax for the Company's next financial year by approximately £2 million. Due to the diversity of the Group's product offerings in both its inhaled drugdelivery and anaesthesia segments, the Board remains confident of the Group'sability to achieve its longer term goals. * Adjusted for special items This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
CSRT.L